News & Views

Weekly Stories about What’s Happening in Washington State and Stories of Interest to Washingtonions

by Gerald Braude

Blood Clotting Disorders in Washington After COVID-19 Shots

The United States Food and Drug Administration (FDA) on Thursday, May 5, 2022 put strict limits on the use of Johnson & Johnson’s COVID-19 shots, citing the risk of a blood clotting condition.  The following day, The Defender issued an article claiming that Pfizer and Moderna pose similar risks.

“According to the latest data from the Vaccine Adverse Event Reporting System (VAERS), between Dec. 14, 2020, and April 29, 2022, there were 13,873 reports of blood-clotting disorders following COVID-19 vaccines in the U.S.”

FDA Limits Use of J&J Vaccine Over Blood Clotting Disorder, But Experts Say Pfizer, Moderna Shots Pose Similar Risk • Children’s Health Defense (childrenshealthdefense.org)

The hyperlink in the above paragraph leads to the following heading on the VAERS site: 

From the 5/6/2022 release of VAERS data:

Found 13,922 cases where Location is U.S., Territories, or Unknown and Vaccine is COVID19 and Symptom is Cerebral venous sinus thrombosis or Cerebral venous thrombosis or Coagulopathy or Deep vein thrombosis or Disseminated intravascular coagulation or Embolism or Idiopathic thrombocytopenic purpura or Immune thrombocytopenia or Immune thrombocytopenic purpura or Ischaemic stroke or Myocardial infarction or Petechiae or Pulmonary embolism or Purpura or Thrombocytopenia or Thrombosis or Vasculitis Search Results from the VAERS Database (medalerts.org)

Of all the blood clotting cases listed above, 474 of them occurred in Washington State. Twenty of those cases resulted in death. Three of those deaths followed the Johnson & Johnson (Janssen) shot. Seventeen reported deaths followed either receipt of a shot from Pfizer or Moderna.

Keep in mind that underreporting is a known major flaw of the VAERS system. See: ICYMI: CDC just published a paper that admits that VAERS is underreported by at least 6.5X

Below is a breakdown of reports by symptom and age from Washington State cases following receipt of a COVID-19 shot.

cerebral venous, sinus thrombosis, or cerebral venous thrombosis: 9

Ages 18-29: 2

Ages 40-49: 1

Ages 50-59: 3

Ages 60-64: 1

Ages 65-79: 1

Unknown: 1

coagulopathy: 2

Age: 36

Age: 52

disseminated intravascular coagulation: 3

The youngest case is a thirty-six-year-old pregnant female (VAERS ID 1127461).

The onset began the day after she took a second Moderna shot on February 5, 2021.  The end of the submitted write-up: 2/11: elevated blood pressure, intermittent bradycardia, continued fetal monitoring, diarrhea improving, transferred to med-tele floor from L&D. labs though to r/o preeclampsia. 2/12: Diarrhea improving, continued tele and fetal monitoring, continued hyponatremia 2/13: fetal heart decels, repeated BPP at 2am and had score of 2/8. Urgent cesarean performed at 5:39 am. Apgars 5/8/8, 33 weeks gestation, 3#6 oz boy, admitted to NICU. I hemorrhaged after the cesarean and had D&C, later diagnosed with DIC and subsequently thought to have severe atypical preeclampsia. Hospital stay extended until 2/20/21 with high blood pressure, episodes of bradycardia, AKI.

deep vein thrombosis: 91

Ages 18-29: 2

Ages 30-39: 10

Ages 40-49: 16

Ages 50-59:23

Ages 60-64: 11

Ages 65-79: 19

80-plus years: 8

Unknown: 2

disseminated intravascular coagulation: 3, with 2 deaths

The first death (VAERS ID 1384860) was a 38-year-old female who took a second Pfizer dose on May 9, 2021 and died on June 8, 2021. The end of the submitted write-up:

Notably patient usually healthy, active, no medications, favorable lipid panel, no illicits; + EtOH binge-drinking last several months but no cirrhosis/ESLD previously doubt primarily Etoh-related process. Pt had ongoing PEA arrests with brief ROSC for approx 7 hrs in field -$g ED $g ICU until death declared.

The second death (VAERS ID 1877549) was a 51-year-old female who took a first Janssen shot on August 12, 2021. Her symptoms began eighteen days later, and she died on September 18, 2021. 

embolism: 2

age: 53

age: 40

Immune thrombocytopenia: 15

Ages 6-17: 1

Ages 18-29: 1 

Ages 40-49: 2

Ages 50-59: 2

Ages 60-64: 1

Ages 65-79: 6

Unknown: 2

The youngest case reported was a 14-year-old female with the following submitted write-up: Acute idiopathic thrombocytopenic purpura; Iron deficiency anemia due to chronic blood loss (VAERS ID: 1430336).

immune thrombocytopenic purpura: 0 reported
ischaemic stroke: 13

Ages 30-39: 5

Ages 40-49: 1

Ages 50-59: 1

Ages 60-64: 1

Ages 65-79: 5

One of those cases resulted in the death of a 35-year-old male (VAERS ID 1499689). He died on June 3, 2021, twenty-three days after taking a first Pfizer dose.  The day before his death, he had an acute basilar ischemic stroke. He was taken in for an emergency thrombectomy, but then experienced progressive edema and ultimately tonsillar herniation.

myocardial infarction: 50

Ages 30-39: 3

Ages 40-49: 10

Ages 50-59: 9

Ages 60-64: 4

Ages 65-79: 12

Ages 80-plus: 7

Unknown:5

Seven of the above myocardial infarction cases have resulted in deaths. Below is the age breakdown: 

Ages 50-59: 2

Ages 60-79: 1

Ages 80-pus: 2

Unknown: 2

Total: 7

Four of those deaths were men; three of the deaths were women.

Petechiae: 26

Ages 3-5: 1

Ages 6-17: 1

Ages 18-29: 1

Ages 30-39: 4

Ages 40-49: 5

Ages 50-59: 6

Ages 60-64: 1

Ages 65-79: 6

Ages 80-plus:1 

The youngest case is a five-year-old male after taking a first Pfizer dose on January 11, 2022. Submitted write-up for VAERS ID 2192216:

Patient developed Henoch-Schoenlein Purpura (HSP) on 1/27/22, beginning with myalgia/arthralgias 16 days after receiving his first COVID-19 vaccine. Family denies any recent/previous viral illnesses prior to onset HSP. Pt had appx 5-6 ”waves” of HSP (typical course) with no sig renal involvement. Hospitalized overnight once for emesis/dehydration, experienced typical petechiae/purpura, arthralgias, abd pains but otherwise well.

pulmonary embolism: 102

Ages 18-29:3

Ages 30-39: 12

Ages 40-49: 13

Ages 50-59: 21

Ages 60-64: 13

Ages 65-79: 29

Ages 80-plus: 10

Unknown: 1

Five of those cases resulted in death: 

  1. A 42-year-old female died on April 15, 2021, one day after onset. 
  2. A 57-year-old male died on May 8, 2021. 
  3. A 94-year-old female died on April 5, 2021. 
  4. An 84-year-old male died on June 13, 2021. 
  5. A 60-year-old male died on September 30, 2021. The County Medical Examiner’s Office wrote that he collapsed on the commode of his home, and the cause of death was  pulmonary thromboembolism due to deep vein thrombosis.
Purpura: 8

Ages 3-5: 1

Ages 6-17: 1

Ages 18-29: 2

Ages 30-39: 1

Ages 40-49: 1

Ages 50-59: 2

The one listed for the 3-5 age range is the same boy detailed above for petechiae. 

thrombocytopenia: 31

Ages 18-29: 3

Ages 30-39: 6

Ages 40-49: 5

Ages 50-59: 2

Ages 60-64: 3

Ages 65-79: 7

Ages 80-plus:3 

Unknown: 2

One of those cases resulted in a death (VAERS ID 1683324) of a 37-year-old female whose onset  began seven days after taking a first Janssen shot on August 21, 2021. She was declared brain dead on September 7. 

thrombosis: 107

Ages 6-17: 1

Ages 18-29: 9

Ages 30-39: 15

Ages 40-49: 22

Ages 50-59: 15

Ages 60-64: 11

Ages 64-79: 18

Ages 80-plus: 7

Unknown: 9

Nine of those cases resulted in death. The ages of four of those deaths are unknown. The other deaths were aged 74, 87, 90, 52, and 76. 

vasculitis: 12

Ages 6-17: 1

Ages 50-59: 5

Ages 60-64: 3

Ages 65-79: 2

Unknown: 1

One of those cases resulted in the death of a 51-year-old female (VAERS ID 1877549) who died on September 18, 2021. Her onset began eighteen days after taking a first Janssen dose on August 12, 2021. 

Print Friendly, PDF & Email
close

Like what you learned? Subscribe to our Feed to get email notice of new posts.

Get new posts by email: